Latest News

New Client Win: Innovator addressing migraine and other indications such as pain, fever, and dysmenorrhea

A US based Innovator has appointed Aagami for evaluation of his Intellectual Property of two patent families and the underlying technology. The o...

Published : 27 Aug 2023

Read More

New Assignment: Existing client from New York has appointed Aagami for supporting strategic Initiatives of their new subsidiary focus on Innovation in Autoimmune diseases

Aagami has a new client. This time it is a new subsidiary of an existing client from New York. The new client is focused on understanding the rol...

Published : 21 Aug 2023

Read More

Aagami to attend BIO-Europe 2023 in Munich, Germany

We are glad to announce that Aagami is attending the International Life Sciences Partnering Conference – BIO-Europe® 2023 (November ...

Published : 17 Aug 2023

Read More

New Client Win: Global pharma with market ready Denosumab biosimilar to PROLIA & XGEVA

The end of July 2023 saw another reputed Global Pharma appoint Aagami for finding partner for ready to commercialize Denosumab Biosimilar in...

Published : 21 Jul 2023

Read More

New Client Win: Japan and US based biotech developing highly effective, non-invasive drugs for CNS targeting neurodegenerative diseases

Aagami are glad to announce that a Japan and US based Biotech has appointed Aagami to support fundraising and partnering of their portfolio of in...

Published : 10 Jul 2023

Read More

New Client: Israeli Medical Device company has awarded Aagami a Market Landscape Research assignment

Aagami has a new client, new assignment for Market Landscape Research. Once completed, the client would appoint Aagami to support their partnerin...

Published : 11 Jun 2023

Read More

Aagami completes BIO International Convention 2023 (June 5-8); its Best ever

Aagami successfully completed BIO International Convention 2023 (June 5-8) in Boston with 45+ one-on-one meetings with decision makers in Biotech, Pha...

Published : 10 Jun 2023

Read More

New Client Win: Pennsylvania Pharma developing smart drug for Myelodysplastic Syndromes (MDS)

Aagami has been appointed by a Pennsylvania Pharma to support their strategic partnering needs. Client is a Biopharma R&D focused company tha...

Published : 15 May 2023

Read More

New Client Win: Portland based Biotech focused on first-in-class NCEs for the treatment of arrhythmia and heart failure.

A Portland based Biotech has appointed Aagami to support their strategic investment and partnering needs.  The CEO of client company has kno...

Published : 12 May 2023

Read More

New Assignment from San Francisco Client with unique technology for making low-cost Natural Melanin

An existing client from San Francisco has awarded a new assignment to Aagami for supporting their fund-raising needs again.  The Client is a...

Published : 01 May 2023

Read More